[Typical and Atypical Ocular Manifestations of Behçet's Disease]

Overview

Journal Ophthalmologe

Specialty Ophthalmology

Date 2012 Jun 16

PMID 22699946

Citations 2

Authors

N Stubiger

U Pleyer

Affiliations

Soon will be listed here.

Abstract

The first ocular symptom in 50-87% of patients with Behçet's disease (BD) is unilateral anterior uveitis. As a characteristic sign of ocular BD the appearance of hypopyon iritis was originally described by Adamantiades and Behçet, but nowadays, probably due to an earlier and more aggressive treatment, this rarely occurs. In the further course of the disease up to 75% of BD patients develop a bilateral chronic relapsing form of posterior uveitis or panuveitis. In addition occlusive retinal vasculitis, which involves arteries as well as veins, is frequently present. A typical complication consists of a cystoid macular edema, which is, besides the retinal vasculitis, responsible for the limited prognosis of visual acuity.

Citing Articles

Neuro-Behçet, pseudotumor cerebri and ocular signs: a rare association.

Rodrigues M, Loureiro C, Geraldo Couceiro A, Reis Ferreira C, Monteiro-Grillo M GMS Ophthalmol Cases. 2016; 3:Doc02.

PMID: 27625934 PMC: 5015602. DOI: 10.3205/oc000012.

Correlation between Ocular Manifestations and Their Complications as Opposed to Visual Acuity and Treatment in Behcet's Disease.

Paovic J, Paovic P, Sredovic V Autoimmune Dis. 2013; 2013:842673.

PMID: 24073331 PMC: 3773399. DOI: 10.1155/2013/842673.

References

Deuter C, Kotter I, Wallace G, Murray P, Stubiger N, Zierhut M . Behçet's disease: ocular effects and treatment. Prog Retin Eye Res. 2007; 27(1):111-36. DOI: 10.1016/j.preteyeres.2007.09.002. View

Wechsler B, Le Hoang P, Le Thi Huong D, Girard B, Rousselie F, Godeau P . [Ocular prognosis in Behçet's disease]. J Fr Ophtalmol. 1992; 15(5):343-7. View

Benezra D, Cohen E . Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol. 1986; 70(8):589-92. PMC: 1040777. DOI: 10.1136/bjo.70.8.589. View

Altenburg A, Papoutsis N, Orawa H, Martus P, Krause L, Zouboulis C . [Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany -- current pathogenetic concepts and therapeutic possibilities]. J Dtsch Dermatol Ges. 2006; 4(1):49-64. DOI: 10.1111/j.1610-0387.2006.05841.x. View

Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M . Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004; 138(3):373-80. DOI: 10.1016/j.ajo.2004.03.022. View

Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K . The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979; 77:225-79. PMC: 1311704. View

Stubiger N, Besch D, Deuter C, Zierhut M, Kotter I . Multifocal ERG changes in patients with ocular Behçet's disease during therapy with interferon alpha 2a. Adv Exp Med Biol. 2003; 528:529-32. DOI: 10.1007/0-306-48382-3_106. View

Krause L . [Adamantiades-Behcet's disease]. Ophthalmologe. 2005; 102(4):329-34. DOI: 10.1007/s00347-004-1166-2. View

Kotter I, Durk H, Saal J, Fierlbeck G, Pleyer U, Ziehut M . Therapy of Behçet's disease. Ger J Ophthalmol. 1996; 5(2):92-7. View

10.

Deuter C, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I . Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum. 2010; 62(9):2796-805. DOI: 10.1002/art.27581. View

11.

Zierhut M, Saal J, Pleyer U, Kotter I, Durk H, Fierlbeck G . Behçet's disease: epidemiology and eye manifestations in German and Mediterranian patients. Ger J Ophthalmol. 1995; 4(4):246-51. View

12.

MAMO J . The rate of visual loss in Behçet's disease. Arch Ophthalmol. 1970; 84(4):451-2. DOI: 10.1001/archopht.1970.00990040453009. View

13.

Pazarli H, Ozyazgan Y, Oguz V, Bahcecioglu H, Muftuoglu A, Yazici H . [Involvement of the fundus oculi in our Behçet patients]. Bull Soc Ophtalmol Fr. 1985; 85(3):317, 320. View